Up-regulation of type 2 iodothyronine deiodinase in dilated cardiomyopathy

Cardiovascular Research

Volumn 87, Issue 4, 2010, Pages 636-646

  Wang, Yuan Yuan ^a   Morimoto, Sachio ^a   Du, Cheng Kun ^a   Lu, Qun Wei ^a,b   Zhan, Dong Yun ^a   Tsutsumi, Takaki ^a   Ide, Tomomi ^a   Miwa, Yosikazu ^a   Takahashi Yanaga, Fumi ^a   Sasaguri, Toshiyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Dilated cardiomyopathy; Hypertrophy; Myocardial infarction; Thyroid hormone

Indexed keywords

CYCLIC AMP; IODOTHYRONINE; IODOTHYRONINE DEIODINASE 2; LIOTHYRONINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROPYLTHIOURACIL; THYROID HORMONE; THYROXINE; TROPONIN T; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEART FUNCTION; HEART INFARCTION; KNOCKOUT MOUSE; LIFE EXPECTANCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; WILD TYPE;

ANIMALS; ANTITHYROID AGENTS; CARDIOMYOPATHY, DILATED; CELLS, CULTURED; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IODIDE PEROXIDASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; MYOCARDIUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROPYLTHIOURACIL; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION, GENETIC; TRIIODOTHYRONINE; TROPONIN T; UP-REGULATION; VENTRICULAR REMODELING;

EID: 77955863477     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq133     Document Type: Article

References (41)

1. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725-1735.
2. Marcisz C, Jonderko G, Wroblewski T, Kurzawska G, Mazur F. Left ventricular mass in patients with hyperthyroidism. Med Sci Monit 2006;12:CR481-CR486.
3. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509.
4. Safirstein SM, Santana O, Agatston AS. Thyrotoxicosis associated with reversible dilated cardiomyopathy. Am Heart J 1994;128:616-617.
5. Bauerlein EJ, Chakko CS, Kessler KM. Reversible dilated cardiomyopathy due to thyrotoxicosis. Am J Cardiol 1992;70:132.
6. Dhadke SV, Dhadke VN. Reversible cardiomyopathy. J Assoc Physicians India 2006;54: 740-741.
7. Londhey VA, Kamble US, Limaye CS, Pednekar SJ, Kini SH, Borges NE. Irreversible dilated cardiomyopathy due to thyrotoxicosis. J Assoc Physicians India 2006;54: 575-576.
8. Watanabe E, Ohsawa H, Noike H, Okamoto K, Tokuyama A, Kanai M et al. Dilated cardiomyopathy associated with hyperthyroidism. Intern Med 1995;34:762-767.
9. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005;26: 704-728.
10. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007;49:71-81.
11. Du CK, Morimoto S, Nishii K, Minakami R, Ohta M, Tadano N et al. Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation. Circ Res 2007;101: 185-194.
12. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res 2008;77:659-666.
13. Baqui MM, Gereben B, Harney JW, Larsen PR, Bianco AC. Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. Endocrinology 2000;141: 4309-4312.
14. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995;269:H2147-H2154.
15. Zhan DY, Morimoto S, Du CK, Wang YY, Lu QW, Tanaka A et al. Therapeutic effect of b-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. Cardiovasc Res 2009;84:64-71.
16. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 2006;116:2571-2579.
17. Kohrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Mol Cell Endocrinol 1999;151:103-119.
18. Gereben B, Salvatore D. Pretranslational regulation of type 2 deiodinase. Thyroid 2005; 15:855-864.
19. Aihara Y, Kurabayashi M, Saito Y, Ohyama Y, Tanaka T, Takeda S et al. Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy: role of M-CAT element within the promoter. Hypertension 2000;36:48-53.
20. Donohue T, Dworkin L, Lango M, Fliegner K, Lango R, Benstein J et al. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994;89:799-809.
21. Brand T, Schneider MD. The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function. J Mol Cell Cardiol 1995;27:5-18.
22. 2+ transport and myocardial relaxation. Circ Res 1994;75:245-251.
23. Kenessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardio-myocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 2006;281: 20666-20672.
24. Kinugawa K, Jeong MY, Bristow MR, Long CS. Thyroid hormone induces cardiac myocyte hypertrophy in a thyroid hormone receptor alpha1-specific manner that requires TAK1 and p38 mitogen-activated protein kinase. Mol Endocrinol 2005;19: 1618-1628.
25. Dillmann WH. Cellular action of thyroid hormone on the heart. Thyroid 2002;12: 447-452.
26. Jansen J, Friesema EC, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid 2005;15:757-768. (Pubitemid 41339256)
27. Kenessey A, Ojamaa K. Ligand-mediated decrease of thyroid hormone receptor-alpha1 in cardiomyocytes by proteosome-dependent degradation and altered mRNA stability. Am J Physiol Heart Circ Physiol 2005;288:H813-H821.
28. Kenessey A, Sullivan EA, Ojamaa K. Nuclear localization of protein kinase C-alpha induces thyroid hormone receptor-alpha1 expression in the cardiomyocyte. Am J Physiol Heart Circ Physiol 2006;290:H381-H389.
29. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538-541.
30. Prahash AJC, Gupta S, Anand IS. Myocyte response to b-adrenergic stimulation is preserved in the noninfarcted myocardium of globally dysfunctional rat hearts after myocardial infarction. Circulation 2000;102:1840-1846.
31. d'Amati G, di Gioia CR, Mentuccia D, Pistilli D, Proietti-Pannunzi L, Miraldi F et al. Increased expression of thyroid hormone receptor isoforms in end-stage human congestive heart failure. J Clin Endocrinol Metab 2001;86:2080-2084.
32. Pantos C, Mourouzis I, Xinaris C, Kokkinos AD, Markakis K, Dimopoulos A et al. Time-dependent changes in the expression of thyroid hormone receptor alpha 1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. Eur J Endocrinol 2007;156:415-424.
33. Trivieri MG, Oudit GY, Sah R, Kerfant BG, Sun H, Gramolini AO et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci USA 2006;103:6043-6048.
34. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ et al. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest 2008;118:975-983.
35. Forini F, Lionetti V, Ardehali H, Pucci A, Cecchetti F, Ghanefar M et al. Early long-term L-T3 replacement rescues mitochondria and prevents ischemic cardiac remodeling in rats. J Cell Mol Med 2010; doi:10.1111/j.1582-4934.2010. 01014.x. Published online ahead of print 20 January 2010.
36. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 1990;16:91-95.
37. Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003;107:708-713.
38. Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med 1995;333:1562-1563.
39. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: meto-prolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
40. Dentice M, Morisco C, Vitale M, Rossi G, Fenzi G, Salvatore D. The different cardiac expression of the type 2 iodothyronine deiodinase gene between human and rat is related to the differential response of the dio2 genes to Nkx-2.5 and GATA-4 transcription factors. Mol Endocrinol 2003;17:1508-1521.
41. Mizukami Y, Yoshioka K, Morimoto S, Yoshida K. A novel mechanism of JNK1 activation. Nuclear translocation and activation of JNK1 during ischemia and reperfusion. J Biol Chem 1997;272:16657-16662.